Surrey Heartlands

Joint Formulary & PAD

Liothyronine sodium - Treatment resistant depression

You are here : Home > Formulary Search > Liothyronine sodium - Treatment resistant depression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Capsules
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
R
Un
Restrictions / Comments :
Important

Initiation by consultant psychiatrists / specialist mental health team only

Documentation

Guidelines (National)
Liothyronine Prescribing Guidance - RMOC - Jun 2019
Evidence Review
Liothyronine for resistant depression - Evidence review - Feb 2016
Evidence Review
Liothyronine CAPSULES - APC briefing paper - March 2022
Patient resource
Liothyronine caps - Patient Information - April 2022.pdf
Miscellaneous
SDCCG - Low value medicines implementation resources - Apr 2018

PAD Profile

ChemicalSubstance :
Liothyronine sodium
Indication :
Treatment resistant depression
Group Name :
Keywords :
TRD, L-T3, L-Tri-iodothyronine sodium, low value medicines, drugs of low clinical value, LVM, drugs of limited clinical value
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5

Other Indications

Below are listed other indications that Liothyronine sodium is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Treatment resistant depression.

Committee Recommendations (1)

01 Nov 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed  that the decision made by APC in March 2016 still stands and a RED traffic light status for Liothyronine (T3) as an option for treatment resistant depression in a niche group of adults whose depression has failed to respond to several antidepressants and is intolerant to lithium augmentation.

Where liothyronine is prescribed for the treatment of depression only, this should be under the care of an NHS consultant psychiatrist.

The most cost-effective formulation should be prescribed at initiation.